Separate Compartment Drug Formulation for Bioequivalence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The administration of rosuvastatin and olmesartan medoxomil in a single matrix formulation leads to drug-drug interaction, delaying the in vivo release and absorption of rosuvastatin, and it is challenging to achieve bioequivalence when formulated in separate compartments using conventional methods.
Innovation Solution
A pharmaceutical composition with separate compartments for olmesartan medoxomil and rosuvastatin or its salt, utilizing disintegrants like crospovidone, low substituted hydroxypropyl cellulose, and croscarmellose sodium to ensure rapid disintegration and bioequivalence, with formulations such as double-layered tablets or pellet-containing capsules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rosuvastatin and olmesartan medoxomil are formulated in a single matrix formulation, then a single dosage form is achieved, but drug-drug interaction occurs that delays in vivo release and absorption of rosuvastatin
Solution Approach 1:
The patent divides the single dosage form into separate compartments: a first compartment containing rosuvastatin and a second compartment containing olmesartan medoxomil. This segmentation prevents direct contact between the two drugs, eliminating the drug-drug interaction that delays rosuvastatin absorption while maintaining the convenience of a single dosage form.
2Device complexity
If conventional formulation methods are used for separate compartments, then structural separation is achieved, but bioequivalence to single formulations cannot be obtained
Solution Approach 1:
The patent optimizes specific formulation parameters within each compartment to achieve bioequivalence. The first compartment contains rosuvastatin with specific excipients including disintegrants (5-20% w/w), binders (5-20% w/w), and fillers (60-85% w/w). The second compartment contains olmesartan medoxomil with optimized excipient ratios. These parameter optimizations ensure that each compartment releases its drug at rates equivalent to the respective single formulations, achieving bioequivalence despite the separate compartment structure.
3Speed
If disintegrants are added to the rosuvastatin compartment, then rapid disintegration is achieved, but formulation complexity increases
Solution Approach 1:
The patent applies disintegrants locally only in the first compartment containing rosuvastatin, rather than throughout the entire formulation. The second compartment containing olmesartan medoxomil uses a different excipient composition optimized for that drug's properties. This local quality approach achieves rapid disintegration where needed while avoiding unnecessary complexity in other parts of the formulation.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a pharmaceutical composition having a single dosage form comprising a compartment comprising olmesartan medoxomil; and a compartment comprising rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil and rosuvastatin or its salt are formulated into a combination dosage form having separate compartments, thereby being able to solve the absorption-inhibition problem originated from drug interaction. In addition, the use of a certain disintegrant(s) makes it possible to obtain a combination formulation bioequivalent to the single formulation of each of drugs.